Sec Form 13G Filing - Wei Zheng filing for CONNECT BIOPHARMA HLDGS LTD (CNTB) - 2022-02-25

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

 

 

Securities and Exchange Commission

Washington, D.C. 20549

 

 

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.     )*

 

 

Connect Biopharma Holdings Limited

(Name of Issuer)

Ordinary shares, par value $0.000174 per share

(Title of Class of Securities)

207523101**

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

**

There is no CUSIP number assigned to the Ordinary Shares of the Issuer (“Ordinary Shares”). CUSIP number 207523101 has been assigned to the American Depositary Shares of the Issuer (“ADSs”). Each ADS represents one Ordinary Share.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 207523101   Schedule 13G   Page 1 of 4

 

  1   

Names of Reporting Persons

 

Zheng Wei

  2  

Check the Appropriate Box if a Member of a Group

(a)  ☐        (b)  ☐

 

  3  

SEC Use Only

 

    

  4  

Citizenship or Place of Organization

 

United States

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

     

Sole Voting Power

 

6,051,244

   6   

Shared Voting Power

 

0

   7   

Sole Dispositive Power

 

6,051,244

   8   

Shared Dispositive Power

 

0

  9  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

6,051,244

10  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11  

Percent of Class Represented by Amount in Row 9

 

11.0%

12  

Type of Reporting Person

 

IN

 


CUSIP No. 207523101   Schedule 13G   Page 2 of 4

 

ITEM 1.    (a)    Name of Issuer:
     

Connect Biopharma Holdings Limited (the “Issuer”).

   (b)    Address of Issuer’s Principal Executive Offices:
     

Science and Technology Park, East R&D Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu, China 215400

ITEM 2.    (a)    Name of Person Filing:
     

This statement is filed on behalf of Zheng Wei (the “Reporting Person”).

   (b)    Address or Principal Business Office:
     

The business address of the Reporting Person is c/o Connect Biopharma Holdings Limited., Science and Technology Park, East R&D Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu, China 215400.

   (c)    Citizenship of each Reporting Person is:
     

Zheng Wei is a citizen of the United States.

   (d)    Title of Class of Securities:
     

Ordinary Shares, par value $0.000174 per share. The Ordinary Shares are sold on the U.S. market as ADSs, each of which represents one Ordinary Share.

   (e)    CUSIP Number:
     

207523101

ITEM 3.      

Not applicable.

ITEM 4.    Ownership.
   (a-c)
  

The ownership information presented below represents beneficial ownership of Ordinary Shares as of December 31, 2021. The percentage calculation is based upon 55,076,319 Ordinary Shares outstanding as of December 31, 2021.


CUSIP No. 207523101   Schedule 13G   Page 3 of 4

 

Reporting Person   

Amount

beneficially

owned

    

Percent

of class:

   

Sole power

to vote or to

direct the

vote:

    

Shared power

to vote or to

direct the

vote:

    

Sole

power to

dispose or

to direct

the

disposition

of:

    

Shared

power to

dispose or

to direct

the

disposition

of:

 

Zheng Wei

     6,051,244        11.0     6,051,244        0        6,051,244        0  

 

  

The Reporting Person is the beneficial owner of 6,051,244 Ordinary Shares, which consists of (i) 5,928,164 Ordinary Shares held of record by the Reporting Person and (ii) 123,080 Ordinary Shares underlying stock options held of record by the Reporting Person that are exercisable as of March 1, 2022.

 

ITEM 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

 

ITEM 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

 

ITEM 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

 

ITEM 8.

Identification and Classification of Members of the Group.

Not applicable.

 

ITEM 9.

Notice of Dissolution of Group.

Not applicable.

 

ITEM 10.

Certification.

Not applicable.


CUSIP No. 207523101   Schedule 13G   Page 4 of 4

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 25, 2022

 

Zheng Wei

/s/ Zheng Wei